Laurent Eckert1, Shaloo Gupta2, Caroline Amand3, Abhijit Gadkari4, Puneet Mahajan5, Joel M Gelfand6. 1. Sanofi, Chilly-Mazarin, France. Electronic address: Laurent.Eckert@sanofi.com. 2. Kantar Health, Princeton, New Jersey. 3. Sanofi, Chilly-Mazarin, France. 4. Regeneron, Tarrytown, New York. 5. Sanofi, Bridgewater, New Jersey. 6. Department of Dermatology and Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: There is a lack of data on the burden of atopic dermatitis (AD) in adults relative to the general population. OBJECTIVE: To characterize the AD burden in adult patients relative to both matched non-AD controls and matched patients with psoriasis in terms of comorbidities, health care resource utilization (HCRU), and costs. METHODS: Adults (≥18 years) who self-reported a diagnosis of AD or psoriasis and adult non-AD controls were identified from the 2013 US National Health and Wellness Survey. Patients with AD were propensity score-matched with non-AD controls and patients with psoriasis on demographic variables. Patient-reported outcomes were analyzed between matched cohorts. RESULTS: Patients with AD had a significantly greater risk for atopic comorbidities, as well as significantly greater HCRU and total cost compared with non-AD controls. The burden of AD was generally comparable to that of psoriasis, although patients with AD reported increased use of emergency room visits compared with patients with psoriasis. LIMITATIONS: Patient-reported data are susceptible to recall bias and erroneous classification. CONCLUSIONS: Adult patients with AD reported a substantial disease burden, suggesting an unmet need for more effective AD treatment options.
BACKGROUND: There is a lack of data on the burden of atopic dermatitis (AD) in adults relative to the general population. OBJECTIVE: To characterize the AD burden in adult patients relative to both matched non-AD controls and matched patients with psoriasis in terms of comorbidities, health care resource utilization (HCRU), and costs. METHODS: Adults (≥18 years) who self-reported a diagnosis of AD or psoriasis and adult non-AD controls were identified from the 2013 US National Health and Wellness Survey. Patients with AD were propensity score-matched with non-AD controls and patients with psoriasis on demographic variables. Patient-reported outcomes were analyzed between matched cohorts. RESULTS:Patients with AD had a significantly greater risk for atopic comorbidities, as well as significantly greater HCRU and total cost compared with non-AD controls. The burden of AD was generally comparable to that of psoriasis, although patients with AD reported increased use of emergency room visits compared with patients with psoriasis. LIMITATIONS: Patient-reported data are susceptible to recall bias and erroneous classification. CONCLUSIONS: Adult patients with AD reported a substantial disease burden, suggesting an unmet need for more effective AD treatment options.
Authors: Michael R Williams; Stephen K Costa; Livia S Zaramela; Shadi Khalil; Daniel A Todd; Heather L Winter; James A Sanford; Alan M O'Neill; Marc C Liggins; Teruaki Nakatsuji; Nadja B Cech; Ambrose L Cheung; Karsten Zengler; Alexander R Horswill; Richard L Gallo Journal: Sci Transl Med Date: 2019-05-01 Impact factor: 17.956
Authors: Mohamed A Kamal; John D Davis; Pavel Kovalenko; Kamal Srinivasan; Eric L Simpson; Takeshi Nakahara; Makoto Sugaya; Atsuyuki Igarashi; Marius Ardeleanu; Christine Xu; Kazuhiko Arima Journal: Clin Transl Sci Date: 2022-08-20 Impact factor: 4.438
Authors: Daniela Weiss; Imke Nordhorn; Linda Tizek; Thomas Werfel; Alexander Zink; Tilo Biedermann; Stephan Traidl; Maximilian C Schielein Journal: Acta Derm Venereol Date: 2021-09-28 Impact factor: 3.875
Authors: Lieneke F M Ariëns; Daphne S Bakker; Lotte S Spekhorst; Jorien Van der Schaft; Judith L Thijs; Inge Haeck; Annebeth E Flinterman; Marijke Kamsteeg; Marie L A Schuttelaar; Marjolein S De Bruin-Weller Journal: Acta Derm Venereol Date: 2021-10-19 Impact factor: 3.875
Authors: Marilyn T Wan; Rebecca L Pearl; Zelma C Chiesa Fuxench; Junko Takeshita; Joel M Gelfand Journal: J Psoriasis Psoriatic Arthritis Date: 2020-06-08
Authors: Steven R Feldman; Linda S Cox; Lindsay C Strowd; Robert A Gerber; Steven Faulkner; Debra Sierka; Timothy W Smith; Joseph C Cappelleri; Mark E Levenberg Journal: Am Health Drug Benefits Date: 2019-04